Your Stroke / Brain Injury Recovery Starts Here


ARNI home-based training and guidance for your rehab is POWERFUL. Accept no substitute.

To mark 20 years of ARNI: Β£50 off Full Set of Stroke Rehab 7 DVDs. Click Here to Get Yours!

News

Elgin Hospital Trial Offers Stroke Hope

Incredible news is coming out of Elgin as Dr Gray’s Hospital begins trialling a pioneering genetic testing device that’s good news for stroke survivors: this cutting-edge technology has the potential to significantly reduce the risk of a patient suffering a second stroke by ensuring they are on the right medication from the very start. This cutting-edge technology has the potential to significantly reduce the risk of a patient suffering a second stroke by ensuring they are placed on the most effective medication from the very start of their recovery.

Traditionally, nine out of ten strokes are caused by blood clots, and the most commonly prescribed preventive drug is Clopi*dogrel. However, nearly 30% of patients carry a specific genetic variation that makes them resistant to this treatment, meaning the standard medication may offer them little to no protection against a follow-up attack.

In the past, identifying whether a patient was resistant to Clopi*dogrel required sending samples to specialized laboratories, a process that could take several days or even weeks to return results. This delay left vulnerable patients at a higher risk during the critical early days following their initial stroke. The new trial at Dr Gray’s Hospital utilises a point-of-care device that provides answers in just 70 minutes. By using a simple mouth swab, healthcare specialists can now determine almost immediately if a patient requires an alternative antiplatelet medication, providing ‘precision medicine’ right at the bedside.

This trial at Dr Gray’s is part of a wider national rollout across NHS Scotland, making it the first initiative of its kind in the UK to integrate routine genetic testing into acute stroke care. The impact of this rapid turnaround is significant as it allows doctors to move away from a one-size-fits-all approach and instead tailor treatment to a patient’s unique genetic makeup. For survivors , this technology offers life-changing peace of mind and a much clearer path to long-term health. The project is expected to have a major ripple effect across the healthcare system by preventing nearly 1,000 secondary strokes over the next five years. Beyond the immeasurable benefit to patients and their families, this innovation is projected to save millions in healthcare and social care costs by reducing hospital stays and long-term disability.


Read More Articles on the ARNI Blog


« |
Share it on

Leave a Comment

Your email address will not be published. Required fields are marked *



We are on Facebook

ARNI